Navigation Links
NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
Date:10/18/2010

CHARLESTON, S.C., Oct. 19 /PRNewswire/ -- The National Association of State Controlled Substances Authorities (NASCSA) announced receipt of a $200,000 grant from Purdue Pharma L.P. today at the organization's 27th annual conference in Charleston, South Carolina. The grant is part of Purdue Pharma's ongoing efforts to support the operation, expansion and awareness of appropriately-designed state prescription drug monitoring programs, which can be an effective tool to address prescription drug abuse and diversion.

NASCSA will manage the solicitation, review and funding of grant proposals. State government agencies or departments will be selected based on an independent review by the NASCSA Special Projects Committee, which consists of association members with expertise in the fields of prescription drug abuse and diversion and prescription drug monitoring programs. Purdue Pharma will have no input into the final selection process.  

"State budgets are shrinking, but the abuse and diversion of prescription drug problem is a growing concern, said Kathy Keough, NASCSA Executive Director. "Purdue Pharma's funding of state prescription drug monitoring programs will help keep these medications out of the wrong hands while ensuring legitimate patients have access to the medications they need."

The grant monies are scheduled to be distributed by NASCSA to various state government departments or agencies with the ability to accept private funding expressly for their state prescription monitoring program by the end of 2011.

"Since 2001, Purdue Pharma has been working to support the implementation of appropriately-designed prescription monitoring programs as one way to help reduce abuse and diversion of prescription medications," said Alan Must, vice president of state government and legislative affairs at Purdue Pharma. "Reducing the abuse of prescription medications will take the combined and coordinated efforts of healthcare professionals, law enforcement, government agencies and local communities. NASCSA is an organization that is uniquely qualified to address the issues of prescription drug abuse from a broad inclusive perspective and we are delighted to provide this funding for this initiative."

The National Association of State Controlled Substances Authorities is a 501(C)(3) non-profit educational organization whose primary purpose is to provide a continuing mechanism through which state and federal agencies can work to increase the effectiveness and efficiency of efforts to prevent and control drug diversion and abuse. NASCSA can be found at www.nascsa.org.

Purdue Pharma L.P. is a privately-held pharmaceutical company known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue Pharma can be found at www.purduepharma.com. Media Contacts:Kathy KeoughNASCSA617-347-1455kathykeough@nascsa.orgLibby HolmanPurdue Pharma L.P.203-588-7670libby.holman@pharma.com
'/>"/>

SOURCE Purdue Pharma L.P.; National Association of State Controlled Substances Authorities
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
2. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
3. ISTA Pharmaceuticals Receives FDA Approval for BROMDAY™
4. Watsons Generic Version of Lotrel ® Receives FDA Approval
5. EntreMed Receives Notice of NASDAQ Compliance
6. Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
7. Greenways PrimeSUITE Receives ONC-ATCB 2011/2012 Certification
8. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
9. Sunridge Receives Reorder on $4 Million Indian Contract
10. Pharmalink AB Receives US Orphan Drug Designation for Nefecon(R) (PL-56)
11. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... -- The global pacemaker market is expected to reach ... report by Grand View Research, Inc. The heightening prevalence ... coverage is a key driving factor governing the growth ... devices are supporting the expansion of this vertical. ... growth rendering driver for this market. A death estimate ...
(Date:1/16/2017)... , Jan. 16, 2017 Derek H. ... Law Firm, was recently appointed Liaison Counsel in ... for all Xarelto cases. In this role, Potts was ... and will actively assist the Court and Co Lead ... Milstein Adelman Jackson Fairchild & Wade ...
(Date:1/16/2017)...  Harrington Discovery Institute at University Hospitals in ... of The Harrington Project for Discovery & Development ... in collaboration with Alzheimer,s Drug Discovery Foundation (ADDF), ... Harrington Discovery Institute collaborations are ... into new medicines that will improve human health, ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... St. Louisans are well-aware of the following facts at present:, ... influenza shot seems to be having no effect on keeping this particularly bad strain of ... people around are coughing, sneezing, or sniffling , These facts are well-known ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon Dr. Mehryar ... official journal of The American Society for Aesthetic Plastic Surgery, in which he ... designed to correct drooping, retracted lower eyelids, which usually result from genetics, injury, ...
(Date:1/16/2017)... ... , ... One thing common to all types of cancer is that it’s ... The money spent screening for and treating cancer in the United States is estimated ... more than in any other country that has an advanced healthcare system, sometimes spending ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... been appointed Chief Executive Officer of the medical device company, effective immediately. , ... Robert Storey. “Kevin has a strong track record in medical device market ...
(Date:1/15/2017)... New York, NY (PRWEB) , ... January 15, 2017 , ... ... growing strategic accounts in the United States for the asthma & allergy friendly mark. ... of America to independently test and identify consumer products to be more suitable for ...
Breaking Medicine News(10 mins):